Search terms
Background
Cancer and hypoxia
Hyperbaric oxygen
HBO and cell survival
HBO and angiogenesis
HBO and metastasis
HBO and chemotherapy
HBO and radiotherapy
HBO and cancer types
Study | Year | Type of study | Cancer type | HBO protocol | Additional therapy | HBO per se | Combo therapy | Metastasis | Angiogenesis |
---|---|---|---|---|---|---|---|---|---|
Breast cancer | |||||||||
Stuhr et al. [47] | 2004 | In vivo | DMBA-induced mammary tumors in rats | 0.2 MPa, 4 exp at 90 min, 11 days or 7 exp, 23 days | 5-FU | ↓ | ↓ | ||
Granowitz et al. [18] | 2005 | In vitro | Mammary cells from normal epithelia, primary tumor, and metastatic tumor + human MCF7 cell line | 0.24 MPa | Melphalan, gemcitabine, and paclitaxel | ↓ | ↓ | ||
Heys et al. [28] | 2006 | Clinical | Locally advanced breast carcinoma | 0.24/0.2 MPa, 90 min daily (5/week) for 10 days | Cyclophosphamide, doxorubicin, and vincristine | ↔ | ↔ | ||
Raa et al. [22] | 2007 | In vivo | DMBA-induced mammary tumors in rats | Hyperoxia (100 % O2) or 0.15 MPa, 4 exp at 90 min over 11 days | 5-FU | ↓ | ↓ | ↓ | |
Haroon et al. [36] | 2007 | In vivo | Mouse mammary adenocarcinoma 4T1-GFP cell line in nu/nu mice | 0.28 MPa for 45 min daily (5/week) up to 5 weeks | ↓ | ||||
Moen et al. [24] | 2009 | In vivo | DMBA-induced mammary tumors in rats | 0.2 MPa, 4 exp at 90 min, 11 days | ↓ | ↓ | |||
Moen et al. [48] | 2009 | In vivo | DMBA-induced mammary tumors in rats | 0.2 MPa, 4 exp at 90 min over 11 days or 1 exp at 90 min | 5-FU | ↓ | |||
Jevne et al. [51] | 2011 | In vivo | Murine 4T1 mammary tumors in NOD/SCID mice | 0.25 MPa, 3 exp at 90 min over 8 days | 5-FU | ↔ | ↓ | ||
Moen et al. [37] | 2012 | In vivo | Murine 4T1 mammary tumors in NOD/SCID mice | 0.25 MPa, 90 min exp, 3 intermittent or 7 daily exp over 8 days | ↓ | (↔/↑) | ↓/↔ | ||
Prostate cancer | |||||||||
Chong et al. [29] | 2004 | In vivo | Human prostate (LNCaP) cells in immunodeficient mice | 0.236 MPa, 20 exp at 90 min, 5/week for 4 weeks | ↔ (↓) | ↔ | |||
Tang et al. [31] | 2009 | In vivo | Human prostate PC-3 cells in immunodeficient mice | 0.2 MPa, 20 exp at 90 min, 5/week for 4 weeks | ↔ | ↔ | |||
Tang et al. [32] | 2009 | In vivo | Human prostate cancer LNCaP cells in immunodeficient mice | 0.2 MPa, 20 exp at 90 min, 5/week for 4 weeks | ↔ | ↔ | |||
Colorectal cancer | |||||||||
Hjelde et al. [66] | 2005 | In vitro | Traditional cell carcinoma (AY-27), Human primary colonadenocarcinoma (WiDr) and human colonadenocarcinoma cell line (SW480) | 0.1, 0.2, 0.3, and 0.4 MPa O2 for 30 min | Photodynamic therapy | ↔ | |||
Daruwalla et al. [38] | 2006 | In vivo | Dimethylhydrazine induced primary colon carcinoma cell line in mice | 0.24 MPa, 90 min daily exp for 7, 13, 19, and 25 days | ↓/↑ | ↔ | (↔) | ||
Daruwalla et al. [39] | 2007 | In vivo | Primary colon carcinoma cell line in mice | 0.24 MPa, 5 times à 90 min over 9 days | SMA–pirarubicin | ↔ | ↓ | ↓ | |
Gliomas | |||||||||
Ogawa et al. [76] | 2006 | Clinical | Patients with high grade gliomas | 0.28 MPa, 30-60 min | Radiotherapy and procarbazine, nimustine, and vincristine | ↔/↓ | |||
Stuhr et al. [23] | 2007 | In vivo | BT4C rat glioma xenografts in nude rats | 100 % O2 or 0.2 MPa HBO, 3 exp at 90 min over 8 days | ↓ | ↓ | |||
Kohshi et al. [75] | 2007 | Clinical | Patients with anaplastic astrocytoma and glioblastoma multiforme | 0.25 MPa, 60 min | Radiotherapy (previous chemotherapy) | ↔/↓ | |||
Suzuki et al. [44] | 2009 | Clinical | Patients with recurrent malignant or brainstem gliomas | 0.2 MPa, 60 min during i.v. adm. of carboplatin + 24 h after drug adm | Carboplatin | ↓ | |||
Other | |||||||||
Chen et al. [20] | 2007 | In vitro | Human leukemia (Jurkat), multiple myeloma (NCl-H929), carcinoma (A549) and breast adenocarcinoma (MCF-7) cell lines | 0.25 or 0.35 MPa oxygen or air for 2–12 h | ↓/↔ | ||||
Ohgami et al. [43] | 2010 | In vitro | Molt-4 human leukemia cells | 0.35 MPa, 90 min | Artemisinin | ↓ | ↓ | ||
Sun et al. [19] | 2004 | In vivo | Human oral cancer cell line in mice | 0.25 MPa, 20 exp. at 90 min | ↔ | ||||
Shi et al. [27] | 2005 | In vivo | Head and neck squamous cell carcinoma (Sq20B and Detroit 562) in mice | 0.24 MPa, 90 min 5 times a week for 2–4 weeks | Radiotherapy (single dose) | ↔ | ↔ | ↔ | |
Schönmeyr et al. [30] | 2008 | In vitro and in vivo | Murine squamous cell carcinoma (SCC-VII) cell line in vitro and in mice | 0.21 MPa 8 daily exp à 90 min | ↔ | ↔ | |||
Ohguri et al. [45] | 2009 | Clinical | Patients with non-small-cell lung cancer (NSCLC) | 0.2 MP, 60–90 min, after chemo and HT | Paclitaxel and carboplatin | ↔/↓ | |||
Kawasoe et al. [21] | 2009 | In vitro and in vivo. | Mouse osteosarcoma (LM8) cell line in vitro and implanted in mice | 0.25 MPa for 90 min | Carboplatin | ↓ | ↓ | ↓ | |
Selvendiran et al. [46] | 2010 | In vivo | Human ovarian cancer xenograft | 0.2 MPa, 90 min daily for up to 21 days | Cisplatin | ↓ | ↓ | ||
Peng et al. [25] | 2010 | In vitro | Nasopharyngeal carcinoma CNE2Z cells | 0.2 MPa, 85 % O2, exp at 90 min (4 h interval) | 5-FU | ↓/↔ | ↓ |